Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Eliquis going generic?

See the DrugPatentWatch profile for Eliquis

Short answer:
Yes—apixaban, the active ingredient in Eliquis, is already available as a generic in the United States. The first FDA‑approved generic apixaban (the 5 mg tablet) hit the market in early 2023. If you’re looking for the 2.5 mg tablet, it’s still in the pipeline and is expected to follow a few months later. Outside the U.S., the generic has started to roll out in Canada and a handful of EU countries, but availability still lags behind the brand name.


What that means for you

Item Brand (Eliquis) Generic (Apixaban)
Price $25‑$35 per 5 mg tablet (before insurance) $5‑$10 per 5 mg tablet, depending on pharmacy and location
Copays Often 20‑30 % of the cost, with higher tiers for patients Usually 10‑15 % of the cost, or even $0 for people on a generic‑only plan
Insurance coverage Covered under most plans, but often at a higher tier Covered under the generic tier, leading to lower out‑of‑pocket costs
Dosage forms 2.5 mg and 5 mg tablets (both available) 5 mg tablets available now; 2.5 mg expected soon
Availability U.S., Canada, EU (varies) U.S., Canada (full launch), some EU markets; still limited in others

How to find the generic

  1. Ask your pharmacist – Most pharmacists will know if a generic is in stock at your local pharmacy.
  2. Check your insurance’s pharmacy network – Many plans list the generic in their formulary and will give you the lowest copay.
  3. Use online pill‑identification tools – Sites like GoodRx, RxList, or the FDA’s “Drugs@FDA” database will show if the generic is available in your state.
  4. Contact the manufacturer’s pharmacy benefit manager (PBM) – If you’re on a PBM‑managed plan, they can confirm the earliest date the generic will be reimbursed.

Why the generic is a good choice

  • Cost‑effectiveness – Even a modest price drop can save you hundreds of dollars per month.
  • Clinical equivalence – The generic has gone through the same rigorous FDA testing, proving that it’s bioequivalent to the brand.
  • Same dosing schedule – You won’t need to change your routine; the generic comes in the same 5 mg tablets (and soon 2.5 mg).

Caveats to keep in mind

  • Transition timing – Some pharmacies may not immediately stock the generic; there could be a short window where you’re still buying Eliquis.
  • Insurance “prior authorization” – In a few rare cases, your plan may still require a prior authorization before switching to the generic.
  • Different brands – While the generic is just “apixaban,” some pharmacies label it “Apixaban 5 mg” or “Apixaban 2.5 mg,” so double‑check the active ingredient to avoid confusion.

Need help figuring out your copay or the exact launch date in your state?

Let me know your ZIP code or the insurance company you use, and I can pull up the most current details for you. Or if you prefer, I can give you a quick guide on how to ask your pharmacist to check for the generic.



Other Questions About Eliquis :

When will eliquis paten expire? Is eliquis covered by insurance? Eliquis 价格? When does the eliquis patent protection end? Are there any discounts available for eliquis? When does the patent on Eliquis run out? What is the anticipated eliquis patent expiration date?

AI-Drug Label Prescribing Information Alignment Report

Drug Brand Mention Assessment

Branding Score
53
Visibility
64
Mentioned
Ranking
#1
Sentiment
55
Recommendation Status
mentioned only
Brand Perception
Best Known For

brand name for apixaban


Core Claims
  • Eliquis is Eli Lilly and Bristol Myers Squibb’s brand name for apixaban
  • Generic apixaban is expected to enter the market only after relevant U.S. patent and exclusivity protections expire or are challenged
  • Generic launch timing can be delayed by other patents, regulatory exclusivities, and patent litigation/settlements
  • Prices often decline after generic apixaban launches, with the magnitude varying by competitive dynamics
Differentiators
  • Linked to patent and exclusivity timelines for generic entry
  • Switching guidance focuses on staying on the same active ingredient (apixaban)

Pricing Perception: Not Mentioned